<DOC>
	<DOCNO>NCT01085656</DOCNO>
	<brief_summary>This study intend determine safety maximum tolerate dose drug , OXi4503 ( combretastatin A1 diphosphate , CA1P , OXiGENE ) , patient relapse refractory AML MDS .</brief_summary>
	<brief_title>A Phase I Clinical Trial OXi4503 Relapsed Refractory AML MDS</brief_title>
	<detailed_description>Despite initial disease remission cytotoxic chemotherapy , patient AML MDS often relapse die disease . Novel strategy target dependent pathway need . AML MDS depend blood vessel survival proliferation . OXi4503 novel microtubule target agent selectively destroy cancer-associated blood vessel , induces cancer cell apoptosis via ortho-quinone moiety result significant regression solid tumor . OXi4503 currently test phase I clinical trial advance solid tumor . In preclinical study human AML , OXi4503 cytotoxic leukemia cell , decrease size chloromas , regress leukemic cell engraftment bone marrow bring phenotypic molecular remission . Given result , hypothesize OXi4503 disease remit effect myeloid malignancy AML MDS . Before evaluate efficacy , safety maximum tolerate dose OXi4503 define AML MDS patient . In addition , assessment pharmacokinetic ( PK ) pharmacokinetic ( PD ) parameter make , relationship dose biologic activity define . Results trial provide new clinical data biologic insight regard effect OXi4503 AML MDS , serve basis future efficacy trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<criteria>Patients must least 18 year age ; Patients must either : AML ( de novo secondary , WHO 2008 classification exclude acute promyelocytic leukemia ) fail achieve CR CRi ( IWG 2003 ) least 1 cycle induction chemotherapy , relapse duration CR CRi ; , MDS ( RAEB1 RAEB2 WHO 2008 classification ) fail achieve hematologic improvement ( IWG 2006 criterion ) least 4 cycle induction therapy ( e.g. , azacitidine , decitabine ) , relapse duration CR PR . ; Patient performance status must Eastern Cooperative Oncology Group ( ECOG ) 0 , 1 2 ; Patients must life expectancy great 14 day ; Patients must total bilirubin ≤ 2 ; Patients must serum AST ALT level ≤ 2.5 time upper limit normal ; Patients must serum creatinine less equal 2.5 time upper limit normal ; Patients must PT/INR PTT normal range ± 25 % ; Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) may participate , provide meet following condition : Must agree use physicianapproved contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , double barrier device ) throughout study three month follow last dose OXi4503 ; Must negative serum urine pregnancy test within 7 day prior begin treatment trial ; Males female partner childbearing potential must agree use physicianapproved contraceptive method ( e.g. , abstinence , condom , vasectomy ) throughout study avoid conceive child 6 month follow last dose OXi4503 ; Written inform consent , willingness , ability comply study procedure . Acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ; Absolute peripheral blood myeloblast count great 25,000/mm3 ; Uncontrolled hypertension , define blood pressure 140/90 mm Hg despite maximum medical intervention ; History congenital long QT syndrome torsades de pointes ; Pathologic bradycardia heart block ( exclude first degree heart block ) ; Prolonged baseline QTc , define QTc interval &gt; 470 msec woman &gt; 450 msec men ; History ventricular arrhythmia ( exclude premature ventricular contraction , PVCs ) ; Major operative surgery within 28 day ; Unstable angina pectoris within 28 day ; Myocardial infarction and/or new ST elevation depression new Q wave ECG within 28 day ; Any history hemorrhagic stroke ; Symptomatic congestive heart failure Class III great ( New York Heart Association Functional Classification ) ; On full dose anticoagulation define warfarin intend raise INR 23 , enoxaparin 1 mg/kg twice day unfractionated heparin intend raise PTT 6090 second ; Major hemorrhagic event within 28 day require transfusion pack red blood cell ; Prior history hypertensive crisis hypertensive encephalopathy ; Active , uncontrolled , clinical significant infection ; Any open wound ; Pregnant nursing patient exclude effect OXi4503 fetus nursing child unknown . Treatment anticancer therapy ( standard investigational ) within previous 21 day prior first dose study drug le full recovery ( CTCAE grade 1 ) clinically significant toxic effect treatment . The use hydroxyurea may use two week dose Cycle 1 ( e.g. , Days 114 dosed hydroxyurea ) . Relative Patients concurrent medication know prolong QTc interval may participate long screen QTc interval meet eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>